Analytical solutions for biologics

Home / Analytical & Solid State Services /

Our comprehensive and flexible analytical solutions are compliant with regulatory requirements and well-designed to ensure the success of your biologic product.

Biologics are complex medicines containing active substances made by a biological process or derived from a biological source. “Biologics” is a broad term and encompasses a wide range of products such as monoclonal antibodies, vaccines (e.g. hepatitis), hormones (e.g. insulin), and enzymes (Enzyme Replacement Therapy).

The majority of biologics are produced in living cells such as human cells, animal cells or microorganisms using recombinant DNA technology methods. Biologics testing is a critical process during development and production as these large molecules are sensitive to and altered by changes in their manufacturing process and therefore quality, safety, and efficacy must be continually monitored and in order to meet strict regulatory requirements.   

Within our state-of-the-art analytical laboratories at Almac, we offer services for GMP lot release and stability testing to support your drug substance and drug product programs for both novel biologics and biosimilars; fit-for-purpose method development and phase-appropriate method validation and raw material testing for microbial and mammalian expression systems.

Almac are also experts in packaging, labelling and distributing biologics.  Discover more here.

All our activities are underpinned by a global cGMP quality system to support the development and launch of clinical and commercial biologics.

The Almac Advantage:

  • Over 15 years’ product release experience adhering to industry regulations including FDA, EMA and PMDA
  • Significant experience with biologics including biosimilars
  • Utilising cGMP compliant phase-appropriate method validation and transfer
  • Fast and flexible development of robust analytical methods utilizing Analytical Quality by Design (AQbD) principles
Contact us
The Almac Advantage:

Philip Nicholl

Business Development, Analytical Lead
Philip started his Almac Journey in 2016 as a placement student within the Spectrometry Services team, specialising in ICP-MS analysis. Following a successful year in industry Philip returned to higher education, graduating from Ulster University with a BSc in Biomedical Science with a diploma in Professional Practice. Philip re-joined Almac as an Analytical Chemist in 2018 and spent close to 4 years honing his analytical abilities within the Mass Spectrometry team with a focus on ICP-MS and LC-MS analyses. Within this role he gained valuable experience in phase appropriate validation and sample analysis to support the development, manufacture, and release of pharmaceuticals. This role allowed him to gain hands on knowledge in structural elucidation, characterisation and identification of both impurities and elemental impurities using newly emerging techniques in the Pharmaceutical Sector such as Peak Purity by LC-MS.

After receiving his MSc with honors from Queens University Belfast in Pharmaceutical Analysis in 2022, he hung up his lab coat to start a new journey in the Business Development team in Almac Sciences, concentrating on its Analytical Services offering. Within this role he works with customers to deliver quotations for Almac’s analytical services and supports the teams across its three analytical testing laboratories.


[email protected]

Follow on LinkedIn

Meet the experts

Pavan Kumar Kunala

Pavan has a strong background in the field of analytical development for biologics, with more than 10 years of experience.

In his previous roles at Intas Biopharmaceuticals and Pfizer, he was responsible for leading a team of scientists to support analytical method development, validation and overall CMC strategy for advancement of early, late and commercial biologics. Pavan holds a M.S. degree in Biological Sciences from Arkansas State University.

Pavan Kumar Kunala
Pavan Kumar Kunala

Pavan has a strong background in the field of analytical development for biologics, with more than 10 years of experience.

In his previous roles at Intas Biopharmaceuticals and Pfizer, he was responsible for leading a team of scientists to support analytical method development, validation and overall CMC strategy for advancement of early, late and commercial biologics. Pavan holds a M.S. degree in Biological Sciences from Arkansas State University.

Related resources

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies